CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade - PubMed (original) (raw)
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade
P A Taylor et al. J Exp Med. 2001.
Abstract
Immune regulatory CD4(+)CD25(+) cells play a vital role in the induction and maintenance of self-tolerance and are essential for T cell homeostasis and the prevention of autoimmunity. Induction of tolerance to allogeneic donor grafts is a clinically desirable goal in bone marrow and solid organ transplantation. To determine whether CD4(+)CD25(+) cells regulate T cell responses to alloantigen and are critical for tolerance induction, murine CD4(+) T cells were tolerized to alloantigen via ex vivo CD40 ligand (CD40L)/CD40 or CD28/cytotoxic T lymphocyte-associated antigen 4/B7 blockade resulting in secondary mixed leukocyte reaction hyporesponsiveness and tolerance to alloantigen in vivo. CD4(+)CD25(+) T cells were found to be potent regulators of alloresponses. Depletion of CD4(+)CD25(+) T cells from the CD4(+) responder population completely abrogated ex vivo tolerance induction to alloantigen as measured by intact responses to alloantigen restimulation in vitro and in vivo. Addback of CD4(+)CD25(+) T cells to CD4(+)CD25(-) cultures restored tolerance induction. These data are the first to indicate that CD4(+)CD25(+) cells are essential for the induction of tolerance to alloantigen and have important implications for tolerance-inducing strategies targeted at T cell costimulatory pathways.
Figures
Figure 1
CD4+CD25+ T cells are required for tolerance induction by CD40L/CD40 costimulatory blockade. (A) Primary MLR culture consisted of 105 cells per well whole CD4+ or CD4+CD25− T cell responders and 105 cells per well bm12 splenic stimulators and/or anti-CD40L mAb. (B) Secondary MLR culture consisted of 104 cells per well responder cells from 9-d bulk cultures as described in (A) and 105 cells per well fresh bm12 stimulators. Tritiated thymidine was added 20 h before harvesting. On the y-axis are mean cpm ± 1 SEM. On the x-axis are days in culture. One of five representative experiments is shown.
Figure 1
CD4+CD25+ T cells are required for tolerance induction by CD40L/CD40 costimulatory blockade. (A) Primary MLR culture consisted of 105 cells per well whole CD4+ or CD4+CD25− T cell responders and 105 cells per well bm12 splenic stimulators and/or anti-CD40L mAb. (B) Secondary MLR culture consisted of 104 cells per well responder cells from 9-d bulk cultures as described in (A) and 105 cells per well fresh bm12 stimulators. Tritiated thymidine was added 20 h before harvesting. On the y-axis are mean cpm ± 1 SEM. On the x-axis are days in culture. One of five representative experiments is shown.
Figure 2
CD4+CD25+ cells regulate alloresponses both in vitro and in vivo_._ (A and B) Primary MLR culture consisted of whole CD4+ or CD4+CD25− T cell responders and bm12 splenic stimulators in the absence (A) or presence (B) of anti-CD40L mAb as in Fig. 1Purified CD4+CD25+ cells were added to CD4+CD25− cells at the percentages indicated on the x-axis. One of three representative experiments is shown. *Significant (P < 0.05) reduction as compared with CD25− culture. (C) 105 naive whole CD4+, CD4+CD25+, whole CD4+ and CD4+CD25−, or whole CD4+ and CD4+CD25+ cells were adoptively transferred into bm12 recipients. On the x-axis are days after transfer of T cells. On the y-axis is the proportion of recipients surviving. CD4+CD25+ versus any other group, P < 0.001, n = 5–8 per group; CD4+ versus CD4+ + CD4+CD25+, P = 0.039; CD4+ versus CD4+ + CD4+CD25−, P = 0.007.
Figure 2
CD4+CD25+ cells regulate alloresponses both in vitro and in vivo_._ (A and B) Primary MLR culture consisted of whole CD4+ or CD4+CD25− T cell responders and bm12 splenic stimulators in the absence (A) or presence (B) of anti-CD40L mAb as in Fig. 1Purified CD4+CD25+ cells were added to CD4+CD25− cells at the percentages indicated on the x-axis. One of three representative experiments is shown. *Significant (P < 0.05) reduction as compared with CD25− culture. (C) 105 naive whole CD4+, CD4+CD25+, whole CD4+ and CD4+CD25−, or whole CD4+ and CD4+CD25+ cells were adoptively transferred into bm12 recipients. On the x-axis are days after transfer of T cells. On the y-axis is the proportion of recipients surviving. CD4+CD25+ versus any other group, P < 0.001, n = 5–8 per group; CD4+ versus CD4+ + CD4+CD25+, P = 0.039; CD4+ versus CD4+ + CD4+CD25−, P = 0.007.
Figure 2
CD4+CD25+ cells regulate alloresponses both in vitro and in vivo_._ (A and B) Primary MLR culture consisted of whole CD4+ or CD4+CD25− T cell responders and bm12 splenic stimulators in the absence (A) or presence (B) of anti-CD40L mAb as in Fig. 1Purified CD4+CD25+ cells were added to CD4+CD25− cells at the percentages indicated on the x-axis. One of three representative experiments is shown. *Significant (P < 0.05) reduction as compared with CD25− culture. (C) 105 naive whole CD4+, CD4+CD25+, whole CD4+ and CD4+CD25−, or whole CD4+ and CD4+CD25+ cells were adoptively transferred into bm12 recipients. On the x-axis are days after transfer of T cells. On the y-axis is the proportion of recipients surviving. CD4+CD25+ versus any other group, P < 0.001, n = 5–8 per group; CD4+ versus CD4+ + CD4+CD25+, P = 0.039; CD4+ versus CD4+ + CD4+CD25−, P = 0.007.
Figure 3
CD4+CD25+ cells upregulate CD40L on their cell surface during incubation with allostimulators. CD4+CD25− (top) and CD4+ CD25+ (bottom) cells were phenotyped for constitutive and inducible expression of CD40L. Dotted line indicates negative control. The thin solid line indicates the constitutive expression of freshly purified naive cells. The bold line indicates CD40L expression after 4-d incubation with allostimulators.
Figure 5
Depletion of CD4+CD25+ cells abrogated protection from GVHD lethality induced by tolerization via costimulatory blockade. 105 cells from washed, 9-d bulk primary MLR cultures as described in Fig. 1 and Fig. 4 were injected into bm12 recipients. (A) Anti-CD40L–tolerization. Two replicate experiments with similar results were pooled; n = 16. CD4+ Anti-CD40L versus any other group, P < 0.001; CD4+ Primed versus CD4+CD25− Primed, P = 0.056. (B) Anti-B7–tolerization. n = 8 per group. CD4+ Anti-B7 versus any other group, P < 0.001.
Figure 5
Depletion of CD4+CD25+ cells abrogated protection from GVHD lethality induced by tolerization via costimulatory blockade. 105 cells from washed, 9-d bulk primary MLR cultures as described in Fig. 1 and Fig. 4 were injected into bm12 recipients. (A) Anti-CD40L–tolerization. Two replicate experiments with similar results were pooled; n = 16. CD4+ Anti-CD40L versus any other group, P < 0.001; CD4+ Primed versus CD4+CD25− Primed, P = 0.056. (B) Anti-B7–tolerization. n = 8 per group. CD4+ Anti-B7 versus any other group, P < 0.001.
Figure 4
CD4+CD25+ T cells are required for tolerance induction by CD28/CTLA-4/B7 costimulatory blockade. (A) Primary MLR culture consisted of whole CD4+ or CD4+CD25− T cell responders and bm12 splenic stimulators and/or anti-B7 mAbs as in Fig. 1. (B) Secondary MLR culture consisted of 104 cells per well responder cells from 9-d bulk cultures as described in (A) and fresh bm12 stimulators. One of four representative experiments is shown.
Figure 4
CD4+CD25+ T cells are required for tolerance induction by CD28/CTLA-4/B7 costimulatory blockade. (A) Primary MLR culture consisted of whole CD4+ or CD4+CD25− T cell responders and bm12 splenic stimulators and/or anti-B7 mAbs as in Fig. 1. (B) Secondary MLR culture consisted of 104 cells per well responder cells from 9-d bulk cultures as described in (A) and fresh bm12 stimulators. One of four representative experiments is shown.
Similar articles
- B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z, Geboes K, Hellings P, Maerten P, Heremans H, Vandenberghe P, Boon L, van Kooten P, Rutgeerts P, Ceuppens JL. Liu Z, et al. J Immunol. 2001 Aug 1;167(3):1830-8. doi: 10.4049/jimmunol.167.3.1830. J Immunol. 2001. PMID: 11466409 - CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses.
Kingsley CI, Karim M, Bushell AR, Wood KJ. Kingsley CI, et al. J Immunol. 2002 Feb 1;168(3):1080-6. doi: 10.4049/jimmunol.168.3.1080. J Immunol. 2002. PMID: 11801641 - Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody.
Taylor PA, Panoskaltsis-Mortari A, Noelle RJ, Blazar BR. Taylor PA, et al. J Immunol. 2000 Jan 15;164(2):612-22. doi: 10.4049/jimmunol.164.2.612. J Immunol. 2000. PMID: 10623802 - Alloantigen specific T regulatory cells in transplant tolerance.
Hall BM, Tran G, Hodgkinson SJ. Hall BM, et al. Int Immunopharmacol. 2009 May;9(5):570-4. doi: 10.1016/j.intimp.2009.01.016. Epub 2009 Jan 29. Int Immunopharmacol. 2009. PMID: 19539571 Review. - Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation.
Appleman LJ, Tzachanis D, Grader-Beck T, Van Puijenbroek AA, Boussiotis VA. Appleman LJ, et al. Leuk Lymphoma. 2002 Jun;43(6):1159-67. doi: 10.1080/10428190290026213. Leuk Lymphoma. 2002. PMID: 12152983 Review.
Cited by
- Differentiation and regulation of CD4+ T cell subsets in Parkinson's disease.
Sun X, Gu R, Bai J. Sun X, et al. Cell Mol Life Sci. 2024 Aug 17;81(1):352. doi: 10.1007/s00018-024-05402-0. Cell Mol Life Sci. 2024. PMID: 39153043 Free PMC article. Review. - Differential induction of donor-reactive Foxp3+ regulatory T cell via blockade of CD154 vs CD40.
Liu D, Yao H, Ferrer IR, Ford ML. Liu D, et al. Am J Transplant. 2024 Aug;24(8):1369-1381. doi: 10.1016/j.ajt.2024.03.033. Epub 2024 Mar 27. Am J Transplant. 2024. PMID: 38552961 - Intragraft memory-like CD127hiCD4+Foxp3+ Tregs maintain transplant tolerance.
Zhao Y, Nicholson L, Wang H, Qian YW, Hawthorne WJ, Jimenez-Vera E, Gloss BS, Lai J, Thomas A, Chew YV, Burns H, Zhang GY, Wang YM, Rogers NM, Zheng G, Yi S, Alexander SI, O'Connell PJ, Hu M. Zhao Y, et al. JCI Insight. 2024 Feb 13;9(6):e169119. doi: 10.1172/jci.insight.169119. JCI Insight. 2024. PMID: 38516885 Free PMC article. - Regulatory T Cells in the Pathogenesis of Graves' Disease.
Kustrimovic N, Gallo D, Piantanida E, Bartalena L, Lai A, Zerbinati N, Tanda ML, Mortara L. Kustrimovic N, et al. Int J Mol Sci. 2023 Nov 17;24(22):16432. doi: 10.3390/ijms242216432. Int J Mol Sci. 2023. PMID: 38003622 Free PMC article. Review. - TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival.
Miura S, Habibabady ZA, Pollok F, Ma M, Rosales IA, Kinoshita K, Pratts S, McGrath G, Chaban R, Fogarty S, Meibohm B, Daugherty B, Lederman S, Pierson RN 3rd. Miura S, et al. Am J Transplant. 2023 Aug;23(8):1182-1193. doi: 10.1016/j.ajt.2023.03.025. Epub 2023 Apr 7. Am J Transplant. 2023. PMID: 37030662 Free PMC article.
References
- Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995;155:1151–1164. - PubMed
- Suri-Payer E., Kehn P.J., Cheever A.W., Shevach E.M. Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells. J. Immunol. 1996;157:1799–1805. - PubMed
- Bonomo A., Kehn P.J., Payer E., Rizzo L., Cheever A.W., Shevach E.M. Pathogenesis of post-thymectomy autoimmunity. Role of syngeneic MLR-reactive T cells. J. Immunol. 1995;154:6602–6611. - PubMed
- Willerford D.M., Chen J., Ferry J.A., Davidson L., Ma A., Alt F.W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995;3:521–530. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI35225/AI/NIAID NIH HHS/United States
- R01 AI34495/AI/NIAID NIH HHS/United States
- 2R37 HL56067/HL/NHLBI NIH HHS/United States
- R01 AI034495/AI/NIAID NIH HHS/United States
- R01 HL063452/HL/NHLBI NIH HHS/United States
- R37 HL056067/HL/NHLBI NIH HHS/United States
- R01 HL63452/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials